钾离子竞争性酸阻滞剂在酸相关疾病中的应用

酸相关疾病是一类消化系统中的常见慢性疾病.质子泵抑制剂现已成为治疗酸相关疾病的一线用药,然而临床应用中逐渐显现出一些局限性,如半衰期短、起效较慢、抑酸不充分、药理作用受CYP2C19基因多态性影响、夜间酸突破等,导致分酸相关疾病患者的症状不能获得充分缓解,以及难治、复发、直接的健康相关生活质量下降和经济负担增大.钾离子...

Application of potassium competitive acid blockers in acidrelated diseases

Acid-related diseases(ARDs)are common chronic diseases of the digestive system.Proton pump inhibitors(PPIs)have become the first-line drugs for the treatment of acid-related diseases.However,PPIs display some limitations in clinical application,such as short half-life,slow action,insufficient acid inhibition,pharmacological effects affected by CYP2C19 gene polymorphism,and nocturnal acid breakthrough,which lead to insufficient symptom remission of ARDs,as well as refractoriness,relapse,and even direct decline in health-related quality of life and increased economic burden.Potassium competitive acid blockers(P-CABs)are a class of novel anti-secretory drugs,which can overcome the limitations of traditional PPIs and show satisfactory acid inhibition effect and safety in clinical application.They may become a new strategy to solve the unsatisfied medical needs in the treatment of ARDs,but their potential adverse reactions remain to be monitored.In this article,we review the challenges in the treatment of acid-related diseases,and the advantages and prospects of P-CABs in the prevention and treatment of ARDs.